Application of advanced MRI techniques to monitor pharmacologic and rehabilitative treatment in multiple sclerosis: current status and future perspectives

References

• Filippi M, Bar-Or A, Piehl F, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018 Nov 8;4(1):43. PubMed PMID: 30410033.
   PubMed Web of Science ®Google Scholar
• Filippi M, Preziosa P, Rocca MA. Magnetic resonance outcome measures in multiple sclerosis trials: time to rethink? Curr Opin Neurol. 2014 Jun;27(3):290–299. PubMed PMID: 24792339.
   PubMed Web of Science ®Google Scholar
• Filippi M, Rocca MA, De Stefano N, et al. Magnetic resonance techniques in multiple sclerosis: the present and the future. Arch Neurol. 2011 Dec;68(12):1514–1520. PubMed PMID: 22159052.
   PubMedGoogle Scholar
• Filippi M, Preziosa P, Rocca MA. Microstructural MR imaging techniques in multiple sclerosis. Neuroimaging Clin N Am. 2017 May;27(2):313–333. PubMed PMID: 28391789.
   PubMed Web of Science ®Google Scholar
• Enzinger C, Barkhof F, Ciccarelli O, et al. Nonconventional MRI and microstructural cerebral changes in multiple sclerosis. Nat Rev Neurol. 2015 Dec;11(12):676–686. PubMed PMID: 26526531.
   PubMed Web of Science ®Google Scholar
• Filippi M, Preziosa P, Rocca MA. Brain mapping in multiple sclerosis: lessons learned about the human brain. Neuroimage. 2017 Sep 14. DOI:10.1016/j.neuroimage.2017.09.021 PubMed PMID: 28917696.
   Google Scholar
• Rocca MA, Battaglini M, Benedict RH, et al. Brain MRI atrophy quantification in MS: from methods to clinical application. Neurology. 2017 Jan 24;88(4):403–413. PubMed PMID: 27986875.
   PubMed Web of Science ®Google Scholar
• Gass A, Rocca MA, Agosta F, et al. MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis. Lancet Neurol. 2015 Apr;14(4):443–454. PubMed PMID: 25748099.
   PubMed Web of Science ®Google Scholar
• Calabrese M, Filippi M, Gallo P. Cortical lesions in multiple sclerosis. Nat Rev Neurol. 2010 Aug;6(8): 438–444. nrneurol.2010.93 [pii].
   PubMed Web of Science ®Google Scholar
• Preziosa P, Rocca MA, Mesaros S, et al. Diagnosis of multiple sclerosis: a multicentre study to compare revised McDonald-2010 and Filippi-2010 criteria. J Neurol Neurosurg Psychiatry. 2018 Mar;89(3):316–318. PubMed PMID: 28724720.
   PubMed Web of Science ®Google Scholar
• Filippi M, Preziosa P, Meani A, et al. Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. Lancet Neurol. 2018 Feb;17(2):133–142. PubMed PMID: 29275979.
   PubMed Web of Science ®Google Scholar
• Calabrese M, Rocca MA, Atzori M, et al. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis. Ann Neurol. 2010 Mar;67(3):376–383. PubMed PMID: 20373349.
   PubMed Web of Science ®Google Scholar
• Sormani M, Stromillo ML, Battaglini M, et al. Modelling the distribution of cortical lesions in multiple sclerosis. Mult Scler. 2012 Feb;18(2):229–231. PubMed PMID: 21757533.
   PubMed Web of Science ®Google Scholar
• Seewann A, Kooi EJ, Roosendaal SD, et al. Postmortem verification of MS cortical lesion detection with 3D DIR. Neurology. 2012 Jan 31;78(5):302–308. PubMed PMID: 22218278.
   PubMed Web of Science ®Google Scholar
• Schmierer K, Wheeler-Kingshott CA, Boulby PA, et al. Diffusion tensor imaging of post mortem multiple sclerosis brain. Neuroimage. 2007 Apr 1;35(2):467–477. S1053-8119(06)01198-0 [pii] PubMed PMID: 17258908.
   PubMed Web of Science ®Google Scholar
• Schmierer K, Scaravilli F, Altmann DR, et al. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol. 2004 Sep;56(3):407–415. PubMed PMID: 15349868.
   PubMed Web of Science ®Google Scholar
• Sled JG. Modelling and interpretation of magnetization transfer imaging in the brain. Neuroimage. 2018 Nov 15;182:128–135. PubMed PMID: 29208570.
   PubMed Web of Science ®Google Scholar
• De Stefano N, Filippi M. MR spectroscopy in multiple sclerosis. J Neuroimaging. 2007 Apr;17(Suppl 1):31S–35S. PubMed PMID: 17425732.
   PubMedGoogle Scholar
• van der Graaf M. In vivo magnetic resonance spectroscopy: basic methodology and clinical applications. Eur Biophys J. 2010 Mar;39(4):527–540. PubMed PMID: 19680645.
   PubMed Web of Science ®Google Scholar
• Nordengen K, Heuser C, Rinholm JE, et al. Localisation of N-acetylaspartate in oligodendrocytes/myelin. Brain Struct Funct. 2015 Mar;220(2):899–917. PubMed PMID: 24379086.
   PubMed Web of Science ®Google Scholar
• Rocca MA, Filippi M. Functional MRI in multiple sclerosis. J Neuroimaging. 2007 Apr;17(Suppl 1):36S–41S. PubMed PMID: 17425733.
   PubMedGoogle Scholar
• Ogawa S, Lee TM, Kay AR, et al. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acad Sci U S A. 1990 Dec;87(24):9868–9872. PubMed PMID: 2124706
   PubMed Web of Science ®Google Scholar
• Biswal BB. Resting state fMRI: a personal history [historical article research support, N.I.H., Extramural review]. Neuroimage. 2012 Aug 15;62(2):938–944. PubMed PMID: 22326802.
   PubMedGoogle Scholar
• Rocca MA, Colombo B, Falini A, et al. Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes. Lancet Neurol. 2005 Oct;4(10):618–626. PubMed PMID: 16168930.
   PubMed Web of Science ®Google Scholar
• Rocca MA, Amato MP, De Stefano N, et al. Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurol. 2015 Mar;14(3):302–317. PubMed PMID: 25662900.
   PubMed Web of Science ®Google Scholar
• Townsend DW. Physical principles and technology of clinical PET imaging. Ann Acad Med Singapore. 2004 Mar;33(2):133–145. PubMed PMID: 15098626.
   PubMed Web of Science ®Google Scholar
• Hogel H, Rissanen E, Vuorimaa A, et al. Positron emission tomography imaging in evaluation of MS pathology in vivo. Mult Scler. 2018 Aug 9:1352458518791680. DOI:10.1177/1352458518791680 PubMed PMID: 30091657.
   Web of Science ®Google Scholar
• Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Oct 31;374(9700):1503–1511. PubMed PMID: 19815268.
   PubMed Web of Science ®Google Scholar
• Comi G, Martinelli V, Rodegher M, et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler. 2013 Jul;19(8):1074–1083. PubMed PMID: 23234810.
   PubMed Web of Science ®Google Scholar
• Filippi M, Rovaris M, Inglese M, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet. 2004 Oct 23–29;364(9444):1489–1496. PubMed PMID: 15500893.
   PubMed Web of Science ®Google Scholar
• Comi G, De Stefano N, Freedman MS, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol. 2012 Jan;11(1):33–41. PubMed PMID: 22146409.
   PubMed Web of Science ®Google Scholar
• Comi G, De Stefano N, Freedman MS, et al. Subcutaneous interferon beta-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study. J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):285–294. PubMed PMID: 28039317.
   PubMed Web of Science ®Google Scholar
• Miller AE, Wolinsky JS, Kappos L, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Oct;13(10):977–986. PubMed PMID: 25192851.
   PubMed Web of Science ®Google Scholar
• Leist TP, Comi G, Cree BA, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 2014 Mar;13(3):257–267. PubMed PMID: 24502830.
   PubMed Web of Science ®Google Scholar
• Ge Y, Grossman RI, Udupa JK, et al. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology. 2000 Feb 22;54(4):813–817. PubMed PMID: 10690968
   PubMed Web of Science ®Google Scholar
• Wolinsky JS, Narayana PA, Johnson KP, et al. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple sclerosis study group and the MRI analysis center. Mult Scler. 2001 Feb;7(1):33–41. PubMed PMID: 11321192.
   PubMedGoogle Scholar
• Rovaris M, Comi G, Rocca MA, et al. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain. 2001 Sep;124(Pt 9):1803–1812. PubMed PMID: 11522582
   PubMedGoogle Scholar
• Sormani MP, Rovaris M, Valsasina P, et al. Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology. 2004 Apr 27;62(8):1432–1434. PubMed PMID: 15111692
   PubMed Web of Science ®Google Scholar
• Khan O, Rieckmann P, Boyko A, et al. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol. 2013 Jun;73(6):705–713. PubMed PMID: 23686821.
   PubMed Web of Science ®Google Scholar
• Cohen J, Belova A, Selmaj K, et al. Equivalence of generic glatiramer acetate in multiple sclerosis: a randomized clinical trial. JAMA Neurol. 2015 Dec;72(12):1433–1441. PubMed PMID: 26458034.
   PubMed Web of Science ®Google Scholar
• Rudick RA, Fisher E, Lee JC, et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple sclerosis collaborative research group. Neurology. 1999 Nov 10;53(8):1698–1704. PubMed PMID: 10563615
   PubMed Web of Science ®Google Scholar
• Hardmeier M, Wagenpfeil S, Freitag P, et al. Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a. Neurology. 2005 Jan 25;64(2):236–240. PubMed PMID: 15668419.
   PubMed Web of Science ®Google Scholar
• De Stefano N, Sormani MP, Stubinski B, et al. Efficacy and safety of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study. J Neurol Sci. 2012 Jan 15;312(1–2):97–101. PubMed PMID: 21880336.
   PubMed Web of Science ®Google Scholar
• Arnold DL, Calabresi PA, Kieseier BC, et al. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial. BMC Neurol. 2017 Feb 10;17(1):29. PubMed PMID: 28183276.
   PubMedGoogle Scholar
• Lublin FD, Cofield SS, Cutter GR, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol. 2013 Mar;73(3):327–340. PubMed PMID: 23424159.
   PubMed Web of Science ®Google Scholar
• O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011 Oct 6;365(14):1293–1303. PubMed PMID: 21991951.
   PubMed Web of Science ®Google Scholar
• Radue EW, Sprenger T, Gaetano L, et al. Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA. Neurol Neuroimmunol Neuroinflamm. 2017 Sep;4(5):e390. PubMed PMID: 28828394.
   PubMed Web of Science ®Google Scholar
• Arnold DL, Gold R, Kappos L, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. J Neurol. 2014 Sep;261(9):1794–1802. PubMed PMID: 24989666.
   PubMed Web of Science ®Google Scholar
• Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012 Mar 15;366(11):1000–1009. PubMed PMID: 22417253.
   PubMed Web of Science ®Google Scholar
• Vollmer TL, Sorensen PS, Selmaj K, et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol. 2014 Apr;261(4):773–783. PubMed PMID: 24535134.
   PubMed Web of Science ®Google Scholar
• Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007 Apr 24;68(17):1390–1401. 68/17/1390 [pii] PubMed PMID: 17452584.
   PubMed Web of Science ®Google Scholar
• Radue EW, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J Neurol Sci. 2010 May 15;292(1–2):28–35. PubMed PMID: 20236661.
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):387–401. PubMed PMID: 20089952.
   PubMed Web of Science ®Google Scholar
• Radue EW, O’Connor P, Polman CH, et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol. 2012 Oct;69(10):1259–1269. 1203630 [pii]. PubMed PMID: 22751847.
   PubMedGoogle Scholar
• Kappos L, O’Connor P, Radue EW, et al. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. Neurology. 2015 Apr 14;84(15):1582–1591. PubMed PMID: 25795646.
   PubMed Web of Science ®Google Scholar
• Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Jun;13(6):545–556. PubMed PMID: 24685276.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):402–415. PubMed PMID: 20089954.
   PubMed Web of Science ®Google Scholar
• Khatri B, Barkhof F, Comi G, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol. 2011 Jun;10(6):520–529. PubMed PMID: 21571593.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Khatri B, Barkhof F, et al. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry. 2016 May;87(5):468–475. PubMed PMID: 26111826.
   PubMed Web of Science ®Google Scholar
• Comi G, Patti F, Rocca MA, et al. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). J Neurol. 2017 Dec;264(12):2436–2449. PubMed PMID: 29063244.
   PubMed Web of Science ®Google Scholar
• Cree BAC, Arnold DL, Cascione M, et al. Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trial. Ther Adv Neurol Disord. 2018;11:1756286418774338. PubMed PMID: 29844796.
   Web of Science ®Google Scholar
• Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012 Nov 24;380(9856):1819–1828. PubMed PMID: 23122652.
   PubMed Web of Science ®Google Scholar
• Havrdova E, Arnold DL, Cohen JA, et al. Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy. Neurology. 2017 Sep 12;89(11):1107–1116. PubMed PMID: 28835401.
   PubMed Web of Science ®Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012 Nov 24;380(9856):1829–1839. PubMed PMID: 23122650.
   PubMed Web of Science ®Google Scholar
• Coles AJ, Cohen JA, Fox EJ, et al. Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology. 2017 Sep 12;89(11):1117–1126. PubMed PMID: 28835403.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017 Jan 19;376(3):221–234. PubMed PMID: 28002679.
   PubMed Web of Science ®Google Scholar
• De Stefano N, Giorgio A, Battaglini M, et al. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Mult Scler. 2018 Feb;24(2):222–226. PubMed PMID: 28140753.
   PubMed Web of Science ®Google Scholar
• Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013 Jun 22;381(9884):2167–2175. PubMed PMID: 23562009.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Radue EW, Havrdova E, et al. Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. J Neurol. 2014 Feb;261(2):316–323. PubMed PMID: 24375015.
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology. 2001 Oct 9;57(7):1239–1247. PubMed PMID: 11591843
   PubMed Web of Science ®Google Scholar
• Rao AB, Richert N, Howard T, et al. Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b. Neurology. 2002 Sep 10;59(5):688–694. PubMed PMID: 12221158
   PubMed Web of Science ®Google Scholar
• Barkhof F, Hulst HE, Drulovic J, et al. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology. 2010 Mar 30;74(13):1033–1040. PubMed PMID: 20200338.
   PubMed Web of Science ®Google Scholar
• Waubant E, Maghzi AH, Revirajan N, et al. A randomized controlled phase II trial of riluzole in early multiple sclerosis. Ann Clin Transl Neurol. 2014 May;1(5):340–347. PubMed PMID: 25356404.
   PubMed Web of Science ®Google Scholar
• Molyneux PD, Kappos L, Polman C, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European study group on interferon beta-1b in secondary progressive multiple sclerosis. Brain. 2000 Nov;123(Pt 11):2256–2263. PubMed PMID: 11050025
   PubMed Web of Science ®Google Scholar
• Fazekas F, Sorensen PS, Filippi M, et al. MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS). Mult Scler. 2005 Aug;11(4):433–440. PubMed PMID: 16042226.
   PubMedGoogle Scholar
• Inglese M, Mancardi GL, Pagani E, et al. Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation. J Neurol Neurosurg Psychiatry. 2004 Apr;75(4):643–644. PubMed PMID: 15026517
   PubMed Web of Science ®Google Scholar
• Roccatagliata L, Rocca M, Valsasina P, et al. The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. Mult Scler. 2007 Sep;13(8):1068–1070. PubMed PMID: 17468445.
   PubMedGoogle Scholar
• Rocca MA, Mondria T, Valsasina P, et al. A three-year study of brain atrophy after autologous hematopoietic stem cell transplantation in rapidly evolving secondary progressive multiple sclerosis. AJNR Am J Neuroradiol. 2007 Oct;28(9):1659–1661. PubMed PMID: 17885242.
   PubMed Web of Science ®Google Scholar
• Chen JT, Collins DL, Atkins HL, et al. Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology. 2006 Jun 27;66(12):1935–1937. PubMed PMID: 16801665.
   PubMed Web of Science ®Google Scholar
• Connick P, Kolappan M, Crawley C, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 2012 Feb;11(2):150–156. PubMed PMID: 22236384.
   PubMed Web of Science ®Google Scholar
• Kapoor R, Ho PR, Campbell N, et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 2018 May;17(5):405–415. PubMed PMID: 29545067.
   PubMed Web of Science ®Google Scholar
• Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018 Mar 31;391(10127):1263–1273. PubMed PMID: 29576505.
   PubMed Web of Science ®Google Scholar
• Chataway J, Schuerer N, Alsanousi A, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet. 2014 Jun 28;383(9936):2213–2221. PubMed PMID: 24655729.
   PubMed Web of Science ®Google Scholar
• Kapoor R, Furby J, Hayton T, et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol. 2010 Jul;9(7):681–688. PubMed PMID: 20621711.
   PubMed Web of Science ®Google Scholar
• Freedman MS, Bar-Or A, Oger J, et al. A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. Neurology. 2011 Oct 18;77(16):1551–1560. PubMed PMID: 21975206.
   PubMed Web of Science ®Google Scholar
• Wolinsky JS, Narayana PA, O’Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007 Jan;61(1):14–24. PubMed PMID: 17262850.
   PubMed Web of Science ®Google Scholar
• Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016 Mar 12;387(10023):1075–1084. PubMed PMID: 26827074.
   PubMed Web of Science ®Google Scholar
• Hawker K, O’Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009 Oct;66(4):460–471. PubMed PMID: 19847908.
   PubMed Web of Science ®Google Scholar
• Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017 Jan 19;376(3):209–220. PubMed PMID: 28002688.
   PubMed Web of Science ®Google Scholar
• Romme Christensen J, Ratzer R, Bornsen L, et al. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial. Neurology. 2014 Apr 29;82(17):1499–1507. PubMed PMID: 24682973.
   PubMed Web of Science ®Google Scholar
• Zajicek J, Ball S, Wright D, et al. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurol. 2013 Sep;12(9):857–865. PubMed PMID: 23856559.
   PubMed Web of Science ®Google Scholar
• Fox RJ, Coffey CS, Conwit R, et al. Phase 2 trial of ibudilast in progressive multiple sclerosis. N Engl J Med. 2018 Aug 30;379(9):846–855. PubMed PMID: 30157388.
   PubMed Web of Science ®Google Scholar
• Chitnis T, Arnold DL, Banwell B, et al. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis. N Engl J Med. 2018 Sep 13;379(11):1017–1027. PubMed PMID: 30207920.
   PubMed Web of Science ®Google Scholar
• Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015 Feb;14(2):183–193. PubMed PMID: 25772897.
   PubMed Web of Science ®Google Scholar
• De Stefano N, Silva DG, Barnett MH. Effect of fingolimod on brain volume loss in patients with multiple sclerosis. CNS Drugs. 2017 Feb 28. DOI:10.1007/s40263-017-0415-2 PubMed PMID: 28247239.
   PubMed Web of Science ®Google Scholar
• Sormani MP, Arnold DL, De Stefano N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol. 2014 Jan;75(1):43–49. PubMed PMID: 24006277.
   PubMed Web of Science ®Google Scholar
• De Stefano N, Arnold DL. Towards a better understanding of pseudoatrophy in the brain of multiple sclerosis patients. Mult Scler. 2015 May;21(6):675–676. PubMed PMID: 25623248.
   PubMed Web of Science ®Google Scholar
• Arnold DL, Kappos L, Hauser SL, et al. Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. In ECTRIMS online library. [cited 2018 Sep 20]. Available from: https://onlinelibraryectrims-congresseu/ectrims/2018/ectrims-2018/228432/douglaslarnoldlong-termreductioninbrainmridiseaseactivityandatrophyhtml. 2018.
   Google Scholar
• Dwyer MG, Zivadinov R, Tao Y, et al. Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial. BMC Neurol. 2015 Nov;11(15):232. PubMed PMID: 26559139.
   PubMed Web of Science ®Google Scholar
• Kaiser CC, Shukla DK, Stebbins GT, et al. A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis. J Neuroimmunol. 2009 Jun 25;211(1–2):124–130. PubMed PMID: 19446890.
   PubMed Web of Science ®Google Scholar
• Filippi M, Rocca MA, Pagani E, et al. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg Psychiatry. 2014 Aug;85(8):851–858. PubMed PMID: 24029546.
   PubMed Web of Science ®Google Scholar
• Gaetano L, Haring DA, Radue EW, et al. Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis. Neurology. 2018 Apr 10;90(15):e1324–e1332. PubMed PMID: 29540589.
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Locatelli L, Cookfair D, et al. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. Mult Scler. 2007 May;13(4):490–501. PubMed PMID: 17463072.
   PubMedGoogle Scholar
• Fisher E, Nakamura K, Lee JC, et al. Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis. Mult Scler. 2016 Apr;22(5):668–676. PubMed PMID: 26238463.
   PubMed Web of Science ®Google Scholar
• Calabrese M, Bernardi V, Atzori M, et al. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis. Mult Scler. 2012 Apr;18(4):418–424. PubMed PMID: 21228025.
   PubMed Web of Science ®Google Scholar
• Vidal-Jordana A, Sastre-Garriga J, Perez-Miralles F, et al. Brain volume loss during the first year of interferon-beta treatment in multiple sclerosis: baseline inflammation and regional brain volume dynamics. J Neuroimaging. 2016 Sep;26(5):532–538. PubMed PMID: 26935253.
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Bergsland N, Hagemeier J, et al. Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures. J Neurol Sci. 2018 May;15(388):175–181. PubMed PMID: 29627017.
   PubMed Web of Science ®Google Scholar
• Vidal-Jordana A, Sastre-Garriga J, Perez-Miralles F, et al. Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Mult Scler. 2013 Aug;19(9):1175–1181. PubMed PMID: 23319072.
   PubMed Web of Science ®Google Scholar
• Mattioli F, Stampatori C, Bellomi F, et al. Natalizumab significantly improves cognitive impairment over three years in ms: pattern of disability progression and preliminary MRI findings. PloS One. 2015;10(7):e0131803. PubMed PMID: 26148120.
   PubMed Web of Science ®Google Scholar
• Khalid F, Tauhid S, Chua AS, et al. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis. Int J Neurosci. 2016 May 27. DOI:10.1080/00207454.2016.1185421 PubMed PMID: 27143245.
   PubMed Web of Science ®Google Scholar
• Ciampi E, Pareto D, Sastre-Garriga J, et al. Grey matter atrophy is associated with disability increase in natalizumab-treated patients. Mult Scler. 2017 Apr;23(4):556–566. PubMed PMID: 27354019.
   PubMed Web of Science ®Google Scholar
• Bajrami A, Pitteri M, Castellaro M, et al. The effect of fingolimod on focal and diffuse grey matter damage in active MS patients. J Neurol. 2018 Jun 25. DOI:10.1007/s00415-018-8952-2 PubMed PMID: 29938336.
   PubMedGoogle Scholar
• Yousuf F, Dupuy SL, Tauhid S, et al. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis. J Neurol Sci. 2017 Dec;15(383):221–229. PubMed PMID: 29146095.
   PubMed Web of Science ®Google Scholar
• Rinaldi F, Calabrese M, Seppi D, et al. Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis. Mult Scler. 2012 Dec;18(12):1760–1767. PubMed PMID: 22570359.
   PubMed Web of Science ®Google Scholar
• Portaccio E, Stromillo ML, Goretti B, et al. Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis–a prospective, non-randomized pilot study. Eur J Neurol. 2013 Jun;20(6):986–990. PubMed PMID: 23057658.
   PubMed Web of Science ®Google Scholar
• Vavasour IM, Tam R, Li DK, et al. A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab. Mult Scler. 2018 Apr 1:1352458518770085. DOI:10.1177/1352458518770085 PubMed PMID: 29663845.
   Google Scholar
• Kalkers NF, Barkhof F, Bergers E, et al. The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult Scler. 2002 Dec;8(6):532–533. PubMed PMID: 12474997.
   PubMedGoogle Scholar
• Lin X, Tench CR, Turner B, et al. Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial. J Neurol Neurosurg Psychiatry. 2003 Aug;74(8):1090–1094. PubMed PMID: 12876240
   PubMed Web of Science ®Google Scholar
• Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology. 2003 Jan 14;60(1):44–51. PubMed PMID: 12525716
   PubMed Web of Science ®Google Scholar
• Dupuy SL, Khalid F, Healy BC, et al. The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis. BMC Med Imaging. 2016 Oct 5;16(1):56. PubMed PMID: 27716096.
   PubMed Web of Science ®Google Scholar
• Montalban X, Sastre-Garriga J, Tintore M, et al. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler. 2009 Oct;15(10):1195–1205. PubMed PMID: 19797261.
   PubMed Web of Science ®Google Scholar
• Singhal T, Tauhid S, Hurwitz S, et al. The effect of glatiramer acetate on spinal cord volume in relapsing-remitting multiple sclerosis. J Neuroimaging. 2017 Jan;27(1):33–36. PubMed PMID: 27466943.
   PubMed Web of Science ®Google Scholar
• Yaldizli Ö, MacManus D, Stutters J, et al. Brain and cervical spinal cord atrophy in primary progressive multiple sclerosis: results from a placebo-controlled phase III trial (INFORMS). In ECTRIMS online library. [cited 2018 Sep 20]. Available from: https://onlinelibraryectrims-congresseu/ectrims/2015/31st/116684/oezgueryaldizlibrainandcervicalspinalcordatrophyinprimaryprogressivehtml. 2015.
   Google Scholar
• Valsasina P, Rocca MA, Horsfield MA, et al. A longitudinal MRI study of cervical cord atrophy in multiple sclerosis. J Neurol. 2015 Jul;262(7):1622–1628. PubMed PMID: 25929665.
   PubMed Web of Science ®Google Scholar
• Tsagkas C, Magon S, Gaetano L, et al. Spinal cord volume loss: A marker of disease progression in multiple sclerosis. Neurology. 2018 Jul 24;91(4):e349–e358. PubMed PMID: 29950437.
   PubMed Web of Science ®Google Scholar
• Rocca MA, Horsfield MA, Sala S, et al. A multicenter assessment of cervical cord atrophy among MS clinical phenotypes. Neurology. 2011 Jun 14;76(24):2096–2102. PubMed PMID: 21670439.
   PubMed Web of Science ®Google Scholar
• Cawley N, Tur C, Prados F, et al. Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis. Mult Scler. 2018 Jun;24(7):932–941. PubMed PMID: 28516804.
   PubMed Web of Science ®Google Scholar
• Geurts JJ, Roosendaal SD, Calabrese M, et al. Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. Neurology. 2011 Feb 1;76(5):418–424. PubMed PMID: 21209373.
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Hussein S, Stosic M, et al. Glatiramer acetate recovers microscopic tissue damage in patients with multiple sclerosis. A case-control diffusion imaging study. Pathophysiology. 2011 Feb;18(1):61–68. PubMed PMID: 20510590.
   PubMedGoogle Scholar
• Ehling R, Di Pauli F, Lackner P, et al. Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial. J Neuroimmunol. 2015 Oct;15(287):98–105. PubMed PMID: 26439969.
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Bergsland N, Hagemeier J, et al. Effect of switching from glatiramer acetate 20mg/daily to glatiramer acetate 40mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study. J Neurol Sci. 2018 Apr;15(387):152–156. PubMed PMID: 29571854.
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Hagemeier J, Bergsland N, et al. Effect of dimethyl fumarate on gray and white matter pathology in subjects with relapsing multiple sclerosis: a longitudinal study. Eur J Neurol. 2018 Mar;25(3):584–e36. PubMed PMID: 29316038.
   PubMed Web of Science ®Google Scholar
• Wiebenga OT, Schoonheim MM, Hulst HE, et al. White matter diffusion changes during the first year of natalizumab treatment in relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol. 2016 Jun;37(6):1030–1037. PubMed PMID: 26965463.
   PubMed Web of Science ®Google Scholar
• Ontaneda D, Sakaie K, Lin J, et al. Measuring brain tissue integrity during 4 years using diffusion tensor imaging. AJNR Am J Neuroradiol. 2017 Jan;38(1):31–38. PubMed PMID: 27659189.
   PubMed Web of Science ®Google Scholar
• Gurevich M, Waknin R, Stone E, et al. Fingolimod-improved axonal and myelin integrity of white matter tracts associated with multiple sclerosis-related functional impairments. CNS Neurosci Ther. 2018 May;24(5):412–419. PubMed PMID: 29316271.
   PubMed Web of Science ®Google Scholar
• Brambilla L, Rossi Sebastiano D, Aquino D, et al. Early effect of dalfampridine in patients with MS: A multi-instrumental approach to better investigate responsiveness. J Neurol Sci. 2016 Sep;15(368):402–407. PubMed PMID: 27538672.
   PubMed Web of Science ®Google Scholar
• Pavisian B, MacIntosh BJ, Szilagyi G, et al. Effects of cannabis on cognition in patients with MS: a psychometric and MRI study. Neurology. 2014 May 27;82(21):1879–1887. PubMed PMID: 24789863.
   PubMed Web of Science ®Google Scholar
• Richert ND, Ostuni JL, Bash CN, et al. Serial whole-brain magnetization transfer imaging in patients with relapsing-remitting multiple sclerosis at baseline and during treatment with interferon beta-1b. AJNR Am J Neuroradiol. 1998 Oct;19(9):1705–1713. PubMed PMID: 9802494
   PubMed Web of Science ®Google Scholar
• Richert ND, Ostuni JL, Bash CN, et al. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis. Mult Scler. 2001 Feb;7(1):49–58. PubMed PMID: 11321194.
   PubMed Web of Science ®Google Scholar
• Brown RA, Narayanan S, Stikov N, et al. MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon beta-1b. Neurology. 2016 Aug 30;87(9):905–911. PubMed PMID: 27473139.
   PubMed Web of Science ®Google Scholar
• Kita M, Goodkin DE, Bacchetti P, et al. Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1a. Neurology. 2000 May 9;54(9):1741–1745. PubMed PMID: 10802778
   PubMed Web of Science ®Google Scholar
• Inglese M, van Waesberghe JH, Rovaris M, et al. The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS. Neurology. 2003 Mar 11;60(5):853–860. PubMed PMID: 12629246
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Dwyer MG, Markovic-Plese S, et al. Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study. PloS One. 2014;9(3):e91098. PubMed PMID: 24625687.
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Dwyer MG, Hussein S, et al. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNbeta-1a in multiple sclerosis. Mult Scler. 2012 Aug;18(8):1125–1134. PubMed PMID: 22194217.
   PubMed Web of Science ®Google Scholar
• Button T, Altmann D, Tozer D, et al. Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab. Mult Scler. 2013 Feb;19(2):241–244. PubMed PMID: 22492133.
   PubMed Web of Science ®Google Scholar
• Chen JT, Collins DL, Atkins HL, et al. Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol. 2008 Feb;63(2):254–262. PubMed PMID: 18257039.
   PubMed Web of Science ®Google Scholar
• Brown RA, Narayanan S, Arnold DL. Segmentation of magnetization transfer ratio lesions for longitudinal analysis of demyelination and remyelination in multiple sclerosis. Neuroimage. 2013 Feb 1;66:103–109. PubMed PMID: 23110887.
   PubMed Web of Science ®Google Scholar
• Filippi M, Rocca MA, Pagani E, et al. European study on intravenous immunoglobulin in multiple sclerosis: results of magnetization transfer magnetic resonance imaging analysis. Arch Neurol. 2004 Sep;61(9):1409–1412. PubMed PMID: 15364687.
   PubMedGoogle Scholar
• Hayton T, Furby J, Smith KJ, et al. Longitudinal changes in magnetisation transfer ratio in secondary progressive multiple sclerosis: data from a randomised placebo controlled trial of lamotrigine. J Neurol. 2012 Mar;259(3):505–514. PubMed PMID: 21904901.
   PubMed Web of Science ®Google Scholar
• Toosy A, Raftopoulos R, Gonzales Quintanilla V, et al. Investigating neuroprotective effects of phenytoin on optic nerve magnetization transfer ratio (MTR) in acute optic neuritis. In ECTRIMS online library. [cited 2018 Sep 20]. Available from: https://onlinelibraryectrims-congresseu/ectrims/2017/ACTRIMS-ECTRIMS2017/200369/ahmedttoosyinvestigatingneuroprotectiveeffectsofphenytoinonoptichtml. 2017.
   Google Scholar
• Sajja BR, Narayana PA, Wolinsky JS, et al. Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study. Mult Scler. 2008 Jan;14(1):73–80. PubMed PMID: 17881390.
   PubMed Web of Science ®Google Scholar
• Sarchielli P, Presciutti O, Tarducci R, et al. 1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study. J Neurol Neurosurg Psychiatry. 1998 Feb;64(2):204–212. PubMed PMID: 9489531
   PubMed Web of Science ®Google Scholar
• Narayanan S, De Stefano N, Francis GS, et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol. 2001 Nov;248(11):979–986. PubMed PMID: 11757963
   PubMed Web of Science ®Google Scholar
• Schubert F, Seifert F, Elster C, et al. Serial 1H-MRS in relapsing-remitting multiple sclerosis: effects of interferon-beta therapy on absolute metabolite concentrations. Magma. 2002 Jun;14(3):213–222. PubMed PMID: 12098564
   PubMedGoogle Scholar
• Yetkin MF, Mirza M, Donmez H. Monitoring interferon beta treatment response with magnetic resonance spectroscopy in relapsing remitting multiple sclerosis. Medicine (Baltimore). 2016 Sep;95(36):e4782. PubMed PMID: 27603381.
   PubMed Web of Science ®Google Scholar
• Toprak MK, Cakir B, Ulu EM, et al. The effects of interferon beta-1a on proton MR spectroscopic imaging in patients with multiple sclerosis, a controlled study, preliminary results. Int J Neurosci. 2008 Dec;118(12):1645–1658. PubMed PMID: 18937112.
   PubMed Web of Science ®Google Scholar
• Wiebenga OT, Klauser AM, Schoonheim MM, et al. Enhanced axonal metabolism during early natalizumab treatment in relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol. 2015 Jun;36(6):1116–1123. PubMed PMID: 25742985.
   PubMed Web of Science ®Google Scholar
• Eisen A, Greenberg BM, Bowen JD, et al. A double-blind, placebo-controlled, single ascending-dose study of remyelinating antibody rHIgM22 in people with multiple sclerosis. Mult Scler J Exp Transl Clin. 2017 Oct-Dec;3(4):2055217317743097. PubMed PMID: 29348926.
   Google Scholar
• Rocca MA, Agosta F, Colombo B, et al. fMRI changes in relapsing-remitting multiple sclerosis patients complaining of fatigue after IFNbeta-1a injection. Hum Brain Mapp. 2007 May;28(5):373–382. PubMed PMID: 16933299.
   PubMed Web of Science ®Google Scholar
• Tomassini V, d’Ambrosio A, Petsas N, et al. The effect of inflammation and its reduction on brain plasticity in multiple sclerosis: MRI evidence. Hum Brain Mapp. 2016 Jul;37(7):2431–2445. PubMed PMID: 26991559.
   PubMed Web of Science ®Google Scholar
• Pavisian B, Staines WR, Feinstein A. Cannabis-induced alterations in brain activation during a test of information processing speed in patients with MS. Mult Scler J Exp Transl Clin. 2015 Jan-Dec;1:2055217315588223. PubMed PMID: 28607694.
   Google Scholar
• Khavari R, Elias SN, Pande R, et al. Higher neural correlates in multiple sclerosis patients with neurogenic overactive bladder following treatment with intradetrusor injection of onabotulinumtoxinA. J Urol. 2018 Aug 1. DOI:10.1016/j.juro.2018.07.066 PubMed PMID: 30076906.
   Web of Science ®Google Scholar
• Parry AM, Scott RB, Palace J, et al. Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine. Brain. 2003 Dec;126(Pt 12):2750–2760. PubMed PMID: 12958082.
   PubMedGoogle Scholar
• Cader S, Palace J, Matthews PM. Cholinergic agonism alters cognitive processing and enhances brain functional connectivity in patients with multiple sclerosis. J Psychopharmacol. 2009 Aug;23(6):686–696. PubMed PMID: 18635705.
   PubMed Web of Science ®Google Scholar
• Huolman S, Hamalainen P, Vorobyev V, et al. The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue. Mult Scler. 2011 Nov;17(11):1351–1361. PubMed PMID: 21846692.
   PubMed Web of Science ®Google Scholar
• Mainero C, Inghilleri M, Pantano P, et al. Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine. Neurology. 2004 Jun 8;62(11):2044–2050. PubMed PMID: 15184612
   PubMed Web of Science ®Google Scholar
• Boutiere C, Rey C, Zaaraoui W, et al. Improvement of spasticity following intermittent theta burst stimulation in multiple sclerosis is associated with modulation of resting-state functional connectivity of the primary motor cortices. Mult Scler. 2017 May;23(6):855–863. PubMed PMID: 27481208.
   PubMed Web of Science ®Google Scholar
• Hulst HE, Goldschmidt T, Nitsche MA, et al. rTMS affects working memory performance, brain activation and functional connectivity in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2017 May;88(5):386–394. PubMed PMID: 27974394.
   PubMed Web of Science ®Google Scholar
• Ratchford JN, Endres CJ, Hammoud DA, et al. Decreased microglial activation in MS patients treated with glatiramer acetate. J Neurol. 2012 Jun;259(6):1199–1205. PubMed PMID: 22160466.
   PubMed Web of Science ®Google Scholar
• Sucksdorff M, Rissanen E, Tuisku J, et al. Evaluation of the effect of fingolimod treatment on microglial activation using serial PET imaging in multiple sclerosis. J Nucl Med. 2017 Oct;58(10):1646–1651. PubMed PMID: 28336784.
   PubMed Web of Science ®Google Scholar
• Pagani E, Hirsch JG, Pouwels PJ, et al. Intercenter differences in diffusion tensor MRI acquisition. J Magn Reson Imaging. 2010 Jun;31(6):1458–1468. PubMed PMID: 20512899.
   PubMed Web of Science ®Google Scholar
• Rocca MA, Agosta F, Sormani MP, et al. A three-year, multi-parametric MRI study in patients at presentation with CIS. J Neurol. 2008 May;255(5):683–691. PubMed PMID: 18274802.
   PubMed Web of Science ®Google Scholar
• Preziosa P, Rocca MA, Pagani E, et al. Structural MRI correlates of cognitive impairment in patients with multiple sclerosis: a multicenter study. Hum Brain Mapp. 2016 Apr;37(4):1627–1644. PubMed PMID: 26833969.
   PubMed Web of Science ®Google Scholar
• Wattjes MP, Barkhof F. Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. Curr Opin Neurol. 2014 Jun;27(3):260–270. PubMed PMID: 24739400.
   PubMed Web of Science ®Google Scholar
• van Den Elskamp IJ, Knol DL, Vrenken H, et al. Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosis. Mult Scler. 2010 Jun;16(6):660–669. PubMed PMID: 20350960.
   PubMed Web of Science ®Google Scholar
• Chen JT, Easley K, Schneider C, et al. Clinically feasible MTR is sensitive to cortical demyelination in MS. Neurology. 2013 Jan 15;80(3):246–252. PubMed PMID: 23269598.
   PubMed Web of Science ®Google Scholar
• Rizzo MA, Hadjimichael OC, Preiningerova J, et al. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004 Oct;10(5):589–595. PubMed PMID: 15471378.
   PubMed Web of Science ®Google Scholar
• Iodice R, Manganelli F, Dubbioso R. The therapeutic use of non-invasive brain stimulation in multiple sclerosis - a review. Restor Neurol Neurosci. 2017;35(5):497–509. PubMed PMID: 28984619.
   PubMed Web of Science ®Google Scholar
• Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003 Nov 8;362(9395):1517–1526. PubMed PMID: 14615106.
   PubMed Web of Science ®Google Scholar
• Romero K, Pavisian B, Staines WR, et al. Multiple sclerosis, cannabis, and cognition: A structural MRI study. Neuroimage Clin. 2015;8:140–147. PubMed PMID: 26106538.
   PubMed Web of Science ®Google Scholar
• Ruffion A, Castro-Diaz D, Patel H, et al. Systematic review of the epidemiology of urinary incontinence and detrusor overactivity among patients with neurogenic overactive bladder. Neuroepidemiology. 2013;41(3–4):146–155. PubMed PMID: 23942583.
   PubMed Web of Science ®Google Scholar
• Chiaravalloti ND, Genova HM, DeLuca J. Cognitive rehabilitation in multiple sclerosis: the role of plasticity. Front Neurol. 2015;6:67. PubMed PMID: 25883585.
   PubMed Web of Science ®Google Scholar
• Lerdal A, Celius EG, Krupp L, et al. A prospective study of patterns of fatigue in multiple sclerosis. Eur J Neurol. 2007 Dec;14(12):1338–1343. PubMed PMID: 17903208.
   PubMed Web of Science ®Google Scholar
• Motl RW, Sandroff BM, Kwakkel G, et al. Exercise in patients with multiple sclerosis. Lancet Neurol. 2017 Oct;16(10):848–856. PubMed PMID: 28920890.
   PubMed Web of Science ®Google Scholar
• Zatorre RJ, Fields RD, Johansen-Berg H. Plasticity in gray and white: neuroimaging changes in brain structure during learning. Nat Neurosci. 2012 Mar 18;15(4):528–536. PubMed PMID: 22426254.
   PubMed Web of Science ®Google Scholar
• Prosperini L, Piattella MC, Gianni C, et al. Functional and structural brain plasticity enhanced by motor and cognitive rehabilitation in multiple sclerosis. Neural Plast. 2015;2015:481574. PubMed PMID: 26064692.
   PubMedGoogle Scholar
• Leavitt VM, Cirnigliaro C, Cohen A, et al. Aerobic exercise increases hippocampal volume and improves memory in multiple sclerosis: preliminary findings. Neurocase. 2014;20(6):695–697. PubMed PMID: 24090098.
   PubMed Web of Science ®Google Scholar
• Rocca MA, Meani A, Fumagalli S, et al. Functional and structural plasticity following action observation training in multiple sclerosis. Mult Scler. 2018 Aug;7:1352458518792771. PubMed PMID: 30084706.
   Google Scholar
• Ibrahim I, Tintera J, Skoch A, et al. Fractional anisotropy and mean diffusivity in the corpus callosum of patients with multiple sclerosis: the effect of physiotherapy. Neuroradiology. 2011 Nov;53(11):917–926. PubMed PMID: 21556863.
   PubMed Web of Science ®Google Scholar
• Bonzano L, Tacchino A, Brichetto G, et al. Upper limb motor rehabilitation impacts white matter microstructure in multiple sclerosis. Neuroimage. 2014 Apr;15(90):107–116. PubMed PMID: 24370819.
   PubMed Web of Science ®Google Scholar
• Prosperini L, Fanelli F, Petsas N, et al. Multiple sclerosis: changes in microarchitecture of white matter tracts after training with a video game balance board. Radiology. 2014 Nov;273(2):529–538. PubMed PMID: 25158046.
   PubMed Web of Science ®Google Scholar
• Rasova K, Prochazkova M, Tintera J, et al. Motor programme activating therapy influences adaptive brain functions in multiple sclerosis: clinical and MRI study. Int J Rehabil Res. 2015 Mar;38(1):49–54. PubMed PMID: 25325167.
   PubMed Web of Science ®Google Scholar
• Tavazzi E, Bergsland N, Cattaneo D, et al. Effects of motor rehabilitation on mobility and brain plasticity in multiple sclerosis: a structural and functional MRI study. J Neurol. 2018 Jun;265(6):1393–1401. PubMed PMID: 29627940.
   PubMed Web of Science ®Google Scholar
• Morgen K, Kadom N, Sawaki L, et al. Training-dependent plasticity in patients with multiple sclerosis. Brain. 2004 Nov;127(Pt 11):2506–2517. PubMed PMID: 15456705.
   PubMedGoogle Scholar
• Rasova K, Krasensky J, Havrdova E, et al. Is it possible to actively and purposely make use of plasticity and adaptability in the neurorehabilitation treatment of multiple sclerosis patients? A pilot project. Clin Rehabil. 2005 Mar;19(2):170–181. PubMed PMID: 15759532.
   PubMed Web of Science ®Google Scholar
• Tomassini V, Johansen-Berg H, Jbabdi S, et al. Relating brain damage to brain plasticity in patients with multiple sclerosis. Neurorehabil Neural Repair. 2012 Jul-Aug;;26(6):581–593. PubMed PMID: 22328685.
   PubMed Web of Science ®Google Scholar
• Leonard G, Lapierre Y, Chen JK, et al. Noninvasive tongue stimulation combined with intensive cognitive and physical rehabilitation induces neuroplastic changes in patients with multiple sclerosis: A multimodal neuroimaging study. Mult Scler J Exp Transl Clin. 2017 Jan-Mar;3(1):2055217317690561. PubMed PMID: 28607750.
   Google Scholar
• Sandroff BM, Motl RW, Scudder MR, et al. Systematic, evidence-based review of exercise, physical activity, and physical fitness effects on cognition in persons with multiple sclerosis. Neuropsychol Rev. 2016 Sep;26(3):271–294. PubMed PMID: 27447980.
   PubMed Web of Science ®Google Scholar
• Sandroff BM, Wylie GR, Sutton BP, et al. Treadmill walking exercise training and brain function in multiple sclerosis: preliminary evidence setting the stage for a network-based approach to rehabilitation. Mult Scler J Exp Transl Clin. 2018 Jan-Mar;4(1):2055217318760641. PubMed PMID: 29497559.
   Google Scholar
• Goverover Y, Chiaravalloti ND, O’Brien A, et al. Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: an updated review of the literature from 2007 to 2016. Arch Phys Med Rehabil. 2018 Feb;99(2):390–407. PubMed PMID: 28958607.
   PubMed Web of Science ®Google Scholar
• Filippi M, Riccitelli G, Mattioli F, et al. Multiple sclerosis: effects of cognitive rehabilitation on structural and functional MR imaging measures–an explorative study. Radiology. 2012 Mar;262(3):932–940. PubMed PMID: 22357892.
   PubMed Web of Science ®Google Scholar
• Bonavita S, Sacco R, Della Corte M, et al. Computer-aided cognitive rehabilitation improves cognitive performances and induces brain functional connectivity changes in relapsing remitting multiple sclerosis patients: an exploratory study. J Neurol. 2015 Jan;262(1):91–100. PubMed PMID: 25308631.
   PubMed Web of Science ®Google Scholar
• Ernst A, Sourty M, Roquet D, et al. Functional and structural cerebral changes in key brain regions after a facilitation programme for episodic future thought in relapsing-remitting multiple sclerosis patients. Brain Cogn. 2016 Jun;105:34–45. PubMed PMID: 27045451.
   PubMed Web of Science ®Google Scholar
• Ernst A, Sourty M, Roquet D, et al. Benefits from an autobiographical memory facilitation programme in relapsing-remitting multiple sclerosis patients: a clinical and neuroimaging study. Neuropsychol Rehabil. 2018 Oct;28(7):1110–1130. PubMed PMID: 27718890.
   PubMed Web of Science ®Google Scholar
• De Giglio L, Upadhyay N, De Luca F, et al. Corpus callosum microstructural changes associated with kawashima nintendo brain training in patients with multiple sclerosis. J Neurol Sci. 2016 Nov;15(370):211–213. PubMed PMID: 27772761.
   PubMed Web of Science ®Google Scholar
• Campbell J, Langdon D, Cercignani M, et al. A randomised controlled trial of efficacy of cognitive rehabilitation in multiple sclerosis: a cognitive, behavioural, and MRI study. Neural Plast. 2016;2016:4292585. PubMed PMID: 28116167.
   PubMed Web of Science ®Google Scholar
• Penner I, Kappos L, Opwis K Induced changes in brain activation using a computerized attention training in patients with multiple sclerosis (MS). Paper Presented at the Proceedings of KogWis05 The German Cognitive Science Conference. 2005; Basel: Schwabe.
   Google Scholar
• Sastre-Garriga J, Alonso J, Renom M, et al. A functional magnetic resonance proof of concept pilot trial of cognitive rehabilitation in multiple sclerosis. Mult Scler. 2011 Apr;17(4):457–467. PubMed PMID: 21177323.
   PubMed Web of Science ®Google Scholar
• Chiaravalloti ND, Wylie G, Leavitt V, et al. Increased cerebral activation after behavioral treatment for memory deficits in MS. J Neurol. 2012 Jul;259(7):1337–1346. PubMed PMID: 22237819.
   PubMed Web of Science ®Google Scholar
• Huiskamp M, Dobryakova E, Wylie GD, et al. A pilot study of changes in functional brain activity during a working memory task after mSMT treatment: the MEMREHAB trial. Mult Scler Relat Disord. 2016 May;7:76–82. PubMed PMID: 27237764.
   PubMed Web of Science ®Google Scholar
• Dobryakova E, Wylie GR, DeLuca J, et al. A pilot study examining functional brain activity 6 months after memory retraining in MS: the MEMREHAB trial. Brain Imaging Behav. 2014 Sep;8(3):403–406. PubMed PMID: 24928632.
   PubMed Web of Science ®Google Scholar
• Ernst A, Botzung A, Gounot D, et al. Induced brain plasticity after a facilitation programme for autobiographical memory in multiple sclerosis: a preliminary study. Mult Scler Int. 2012;2012:820240. PubMed PMID: 23125932.
   PubMedGoogle Scholar
• Parisi L, Rocca MA, Valsasina P, et al. Cognitive rehabilitation correlates with the functional connectivity of the anterior cingulate cortex in patients with multiple sclerosis. Brain Imaging Behav. 2014 Sep;8(3):387–393. PubMed PMID: 22528829.
   PubMed Web of Science ®Google Scholar
• Parisi L, Rocca MA, Mattioli F, et al. Changes of brain resting state functional connectivity predict the persistence of cognitive rehabilitation effects in patients with multiple sclerosis. Mult Scler. 2014 May;20(6):686–694. PubMed PMID: 24072724.
   PubMed Web of Science ®Google Scholar
• Cerasa A, Gioia MC, Valentino P, et al. Computer-assisted cognitive rehabilitation of attention deficits for multiple sclerosis: a randomized trial with fMRI correlates. Neurorehabil Neural Repair. 2013 May;27(4):284–295. PubMed PMID: 23192417.
   PubMed Web of Science ®Google Scholar
• Leavitt VM, Wylie GR, Girgis PA, et al. Increased functional connectivity within memory networks following memory rehabilitation in multiple sclerosis. Brain Imaging Behav. 2014 Sep;8(3):394–402. PubMed PMID: 22706694.
   PubMed Web of Science ®Google Scholar
• Hubacher M, DeLuca J, Weber P, et al. Cognitive rehabilitation of working memory in juvenile multiple sclerosis-effects on cognitive functioning, functional MRI and network related connectivity. Restor Neurol Neurosci. 2015;33(5):713–725. PubMed PMID: 25835556.
   PubMed Web of Science ®Google Scholar
• De Giglio L, Tona F, De Luca F, et al. Multiple sclerosis: changes in thalamic resting-state functional connectivity induced by a home-based cognitive rehabilitation program. Radiology. 2016 Jul;280(1):202–211. PubMed PMID: 26953867.
   PubMed Web of Science ®Google Scholar
• Pareto D, Sastre-Garriga J, Alonso J, et al. classic block design “pseudo”-resting-state fMRI changes after a neurorehabilitation program in patients with multiple sclerosis. J Neuroimaging. 2018 May;28(3):313–319. PubMed PMID: 29400912.
   PubMed Web of Science ®Google Scholar
• Mattioli F, Bellomi F, Stampatori C, et al. Neuroenhancement through cognitive training and anodal tDCS in multiple sclerosis. Mult Scler. 2016 Feb;22(2):222–230. PubMed PMID: 26014600.
   PubMed Web of Science ®Google Scholar
• De Stefano N, Stromillo ML, Giorgio A, et al. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016 Jan;87(1):93–99. PubMed PMID: 25904813.
   PubMed Web of Science ®Google Scholar
• Kappos L, De Stefano N, Freedman MS, et al. Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler. 2016 Sep;22(10):1297–1305. PubMed PMID: 26585439.
   PubMed Web of Science ®Google Scholar
• Storelli L, Rocca MA, Pagani E, et al. Measurement of whole-brain and gray matter atrophy in multiple sclerosis: assessment with MR imaging. Radiology. 2018 Aug;288(2):554–564. PubMed PMID: 29714673.
   PubMed Web of Science ®Google Scholar
• Bodini B, Veronese M, Garcia-Lorenzo D, et al. Dynamic imaging of individual remyelination profiles in multiple sclerosis. Ann Neurol. 2016 Feb 18. DOI:10.1002/ana.24620 PubMed PMID: 26891452.
   Web of Science ®Google Scholar